The brain's workhorse endocannabinoid. 2-AG is made on demand from membrane lipids and travels backward across synapses — the retrograde messenger that tells presynaptic terminals to calm down.
2-AG is not stored — it is synthesized when needed: postsynaptic calcium and Gq-coupled receptor activity trigger phospholipase C and diacylglycerol lipase in sequence, liberating 2-AG from diacylglycerol. It diffuses backward to presynaptic CB1 receptors, is degraded within minutes by monoacylglycerol lipase, and its arachidonate feeds the eicosanoid cascade. Full map at the endocannabinoid system pathway.
Receptor Actions
CB1 receptors on presynaptic terminals: Gi-coupled suppression of calcium channels — less transmitter released.
Depolarization-induced suppression: the retrograde signal discovered as DSI — 2-AG's signature effect.
CB2 on immune cells: the anti-inflammatory arm, pharmacology's quiet target.
Physiological Role
Synaptic gain control: adjusts release probability — the brain's tuning knob at every synapse cluster.
Appetite, stress buffering, and reward circuit modulation through hypothalamic and limbic CB1.
Synthesized from DAG — a second-messenger lipid doubling as endocannabinoid precursor.
Terminated by MGLL — the enzyme that sets 2-AG's lifetime.
Sibling endocannabinoid anandamide: different synthesis, same receptors, shorter career.
Clinical Relevance
Cannabis works at the receptors 2-AG built — THC borrows the retrograde system.
MGLL inhibitors raise 2-AG for pain and anxiety — the anandamide-sparing drug strategy.
Epilepsy and PTSD research targets this system's gain control.
Brain 2-AG turnover is the highest of any signaling lipid — the system runs fast, tuned by millisecond need.
2-AG is the agonist that CB1 receptors evolved around — full efficacy, abundant supply, tight temporal control by its hydrolase.
Short-term plasticity assays isolate 2-AG's contribution pharmacologically: block its synthesis and retrograde suppression disappears within the slice.